Compare BDX & IDXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDX | IDXX |
|---|---|---|
| Founded | 1897 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0B | 45.4B |
| IPO Year | 1998 | 1996 |
| Metric | BDX | IDXX |
|---|---|---|
| Price | $176.03 | $588.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $186.00 | ★ $721.67 |
| AVG Volume (30 Days) | ★ 1.7M | 626.6K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | ★ 22.59 |
| EPS | 0.25 | ★ 7.74 |
| Revenue | ★ $21,840,000,000.00 | $4,303,702,000.00 |
| Revenue This Year | N/A | $10.88 |
| Revenue Next Year | $3.02 | $8.59 |
| P/E Ratio | $682.64 | ★ $75.55 |
| Revenue Growth | 8.24 | ★ 10.42 |
| 52 Week Low | $140.11 | $518.55 |
| 52 Week High | $213.08 | $769.98 |
| Indicator | BDX | IDXX |
|---|---|---|
| Relative Strength Index (RSI) | 72.34 | 58.13 |
| Support Level | $163.44 | $536.07 |
| Resistance Level | $196.05 | $583.93 |
| Average True Range (ATR) | 3.72 | 16.28 |
| MACD | 1.47 | 3.13 |
| Stochastic Oscillator | 96.76 | 52.32 |
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.